Canada Life’s NextCure NXTC Stock Holding History

Canada Life’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-79	Closed	-$9K	–	2580
2021 Q1	$9K	Hold	79	–	–	﹤0.01%	2561
2020 Q4	$10K	Hold	79	–	–	﹤0.01%	2593
2020 Q3	$8K	Hold	79	–	–	﹤0.01%	2535
2020 Q2	$20K	Buy	+79	New	+$30.1K	﹤0.01%	2496

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Canada Life's NXTC Position: Q2 2021 in Review

Canada Life sold out of NextCure (NXTC) in Q2 2021, closing a stake of 79 shares — an estimated $9K sold.

Canada Life first reported a position in NXTC in Q2 2020 and held it in 4 quarters. The position peaked at $20K in Q2 2020. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

Canada Life reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
Canada Life sold 79 NextCure shares in Q2 2021, an estimated $9K.
Canada Life first reported a position in NextCure in Q2 2020 and held it in 4 quarters.
Canada Life's NextCure position peaked at $20K in Q2 2020.
78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on Canada Life's 13F filing for Q2 2021, filed 11 Aug 2021.